ERBB2 and metastatic malignant neoplasm: This is an open-label, non-randomized phase I clinical trial (NCT01730118) in patients with advanced metastatic cancers who have progressed after a minimum of one standard therapy, whose tumor is HER2 immunohistochemistry (IHC) score 1+, 2+ or 3+ or HER2/CEP17 ratio ≥ 1.8 by FISH.